公开(公告)号：US20230167100A1

公开(公告)日：2023-06-01

申请号：US17919490

申请日：2021-08-10

Applicant: Novartis AG

Inventor： Xuan DAI ,  Michael DORE ,  Xiang-Ju Justin GU ,  Ling LI ,  Kun Chin LIU ,  Sing Yeung Frankie MAK ,  Yuan MI ,  Counde OYANG ,  Julien PAPILLON ,  Wei (Vicky) QI ,  Xiaoxia YAN ,  Zhengtian YU ,  Ji Yue (Jeff) ZHANG ,  Kehao ZHAO

IPC: C07D405/14 ,  A61K45/06

CPC classification number: C07D405/14 ,  A61K45/06

Abstract: The invention disclosed herein relates to aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds, and the use of such compounds for treating a disease or condition mediated by Enhancer of Zeste Homolog 2 (EZH2), Polycomb Repressive Complex 2 (PRC2), or a combination thereof.

公开(公告)号：US20230121768A1

公开(公告)日：2023-04-20

申请号：US17772888

申请日：2021-05-27

Applicant: NOVARTIS AG

Inventor： Zhenting GAO ,  Haibing GUO ,  Ming LI ,  Kun Chin LIU ,  Chunliang LU ,  Zhuming SUN ,  Yihui ZHU

IPC: C07D473/34 ,  A61P35/02 ,  A61K31/52 ,  C07D487/04 ,  A61K31/53 ,  C07D471/04 ,  A61K31/437

Abstract: The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by mixed lineage leukemia 1 (MLL1).